Mechanisms and predictions of drug-drug interactions of the hepatitis C virus three direct-acting antiviral regimen: Paritaprevir/ritonavir, ombitasvir, and dasabuvir

Drug Metabolism and Disposition

Volumn 45, Issue 7, 2017, Pages 755-764

  Shebley, Mohamad ^a,b   Liu, Jinrong ^a   Kavetskaia, Olga ^a   Sydor, J ^a   De Morais, Sonia M ^a   Fischer, Volker ^a   Nijsen, Marjoleen J M A ^a   Bow, Daniel A J ^a  

^a Drug Metabolism   (United States)

^b ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; DASABUVIR; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; OMBITASVIR; PARITAPREVIR; RITONAVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; CARRIER PROTEIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; MACROCYCLIC COMPOUND; MULTIDRUG RESISTANCE PROTEIN 1; SULFONAMIDE; URACIL;

ANIMAL CELL; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSPORT; EMBRYO; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; DRUG INTERACTION; HEK293 CELL LINE; HEPACIVIRUS; METABOLISM; PHYSIOLOGY;

ANILIDES; ANTIVIRAL AGENTS; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; CARBAMATES; CELL LINE; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HEK293 CELLS; HEPACIVIRUS; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MEMBRANE TRANSPORT PROTEINS; RITONAVIR; SULFONAMIDES; URACIL;

EID: 85020907428     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.116.074518     Document Type: Article

References (33)

1. Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, Bernstein B, Awni W, and Menon R (2015) Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 15: 1313–1322.
2. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60: 508–518.
3. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, et al. (2013) Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 58: 792–800.
4. Chiou WJ, de Morais SM, Kikuchi R, Voorman RL, Li X, and Bow DA (2014) In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44: 276–282.
5. Fahrmayr C, Fromm MF, and König J (2010) Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 42: 380–401.
6. FDA (2012) Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, U.S. Food and Drug Administration, Rockville, MD.
7. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, et al. (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594–1603.
8. Gartzke D and Fricker G (2014) Establishment of optimized MDCK cell lines for reliable efflux transport studies. J Pharm Sci 103: 1298–1304.
9. Ieiri I, Tsunemitsu S, Maeda K, Ando Y, Izumi N, Kimura M, Yamane N, Okuzono T, Morishita M, Kotani N, et al. (2013) Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol 53: 654–661.
10. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53: 73–87.
11. Khalilieh S, Feng HP, Hulskotte EG, Wenning LA, and Butterton JR (2015) Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions. Clin Pharmacokinet 54: 599–614.
12. Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, and Menon R (2016) Evaluation of drug-drug interactions between hepatitis C antiviral agents ombitasvir, paritaprevir/ritonavir, and dasabuvir and HIV-1 protease inhibitors. Clin Infect Dis 62: 972–979.
13. Kikuchi R, Lao Y, Bow DA, Chiou WJ, Andracki ME, Carr RA, Voorman RL, and De Morais SM (2013) Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci 102: 4426–4432.
14. Kirby BJ, Symonds WT, Kearney BP, and Mathias AA (2015) Pharmacokinetic, pharmacody-namic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 54: 677–690.
15. Kumar GN, Rodrigues AD, Buko AM, and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277: 423–431.
16. Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, and Wedemeyer H (2013) The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther 38: 1365–1372.
17. Menon R, Badri P, Khatri A, Wang T, Bow DA, Polepally A, Podsadecki T, Awni WM, and Dutta S (2014) ABT-450/ritonavir +ombitasvir + dasabuvir: drug interactions mediated by transporters in 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; 2014 May 19–21; Washington, DC.
18. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, et al. (2015) Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 63: 20–29.
19. Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, and Dutta S (2016) Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: combined analysis from 9 phase 1b/2 studies. AAPS J 18: 270–280.
20. Nader AM and Foster DR (2014) Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity. J Clin Pharmacol 54: 3–13.
21. Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, and Rostami-Hodjegan A (2013) Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci 102: 3161–3173.
22. Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, and Menon RM (2016) Drug-drug interactions between the anti-hepatitis C virus 3D regimen of ombitasvir, paritaprevir/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers. Clin Pharmacokinet 55: 1003–1014.
23. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39: 298–309.
24. Shen J, Serby M, Reed A, Lee AJ, Menon R, Zhang X, Marsh K, Wan X, Kavetskaia O, and Fischer V (2016a) Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos 44: 1139–1147.
25. Shen J, Serby M, Surber B, Lee AJ, Ma J, Badri P, Menon R, Kavetskaia O, de Morais SM, Sydor J, et al. (2016b) Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans. Drug Metab Dispos 44: 1148–1157.
26. Shi JG, Zhang Y, and Yeleswaram S (2011) The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nat Rev Drug Discov 10: 75–, author reply 75.
27. Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, Benítez-Gutiérrez L, and Peña JM (2015) Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 11: 333–341.
28. Templeton IE, Chen Y, Mao J, Lin J, Yu H, Peters S, Shebley M, and Varma MV (2016) CPT Pharmacometrics. Syst Pharmacol 5(10): 505–515.
29. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, and Bergman A (2012) Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29: 2860–2873.
30. Viekira Pak (2014) U.S. prescribing information. AbbVie Inc., North Chicago, IL.
31. World Health Organization (2011) Hepatitis C. Wkly Epidemiol Rec 86: 445–447.
32. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Jr, Klein CE, Rublein JC, and Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42: 52–60.
33. Zhou J, Tracy TS, and Remmel RP (2011) Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos 39: 322–329.